Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
OCULAR THERAPEUTIX, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Investor focus: product revenue, cash runway, operating expenses, and pipeline updates in the exhibit
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net revenue $12.9M vs $14.5M; net loss widened to $94.8M, or $0.42/share
- Cash $530.6M supports planned operations into 2028, excluding full manufacturing and commercial scale-up costs
- AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 under FDA’s 505(b)(2) pathway
- SOL-R Week 52 interim safety analysis planned for 4Q 2026, supporting NDA safety dataset exceeding 300 patients with one-year follow-up
- SOL-R primary endpoint moved to Week 40, with topline results targeted for 1Q 2028 and key secondary endpoints at Weeks 56 and 96
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OCULAR THERAPEUTIX, INC 8-K filings
Get the next OCUL 8-K as it lands
Follow OCUL for push alerts, or ask the research agent what this filing means.